The Boston Globe

March 20, 2015 10:30 PM

4 0

The Boston Globe

Alzheimer’s has long been a scourge for tens of millions of people, gradually robbing them of their memory and cognition, ultimately impairing the ability to perform basic tasks. The dreaded disease has stubbornly eluded treatment for decades.

But early-stage study results released Friday offered a jolt of hope, showing an experimental drug from Cambridge biotech Biogen Idec Inc. slowed the mental decline of a small number of patients with early indications and mild cases of the neurodegenerative disorder.

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page